Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5259088 | 0.84 | ITGB1 (0.41) | FFAR1DRD1 | |
| SCHEMBL5262526 | 0.82 | DRD1 (0.31) | DRD1 | |
| SCHEMBL5147512 | 0.80 | FFAR1 (0.38) | FFAR1DRD1GRM4PTGER4CYP3A4 | |
| SCHEMBL5261691 | 0.79 | DRD1 (0.36) | FFAR1DRD1ACACB | |
| SCHEMBL7259517 | 0.79 | FFAR1 (0.38) | FFAR1DRD1GRM4PTGER4CYP3A4 | |
| SCHEMBL5147705 | 0.79 | FFAR1 (0.34) | FFAR1DRD1 | |
| SCHEMBL5149383 | 0.78 | FFAR1 (0.37) | FFAR1DRD1GRM4PTGER4CYP3A4 | |
| SCHEMBL5261699 | 0.78 | FFAR1 (0.35) | FFAR1DRD1ACACB | |
| SCHEMBL5148581 | 0.78 | FFAR1 (0.36) | FFAR1DRD1GRM4PTGER4CYP3A4 | |
| SCHEMBL5261700 | 0.78 | FFAR1 (0.35) | FFAR1DRD1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332132-B1 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | UCB PHARMA SA (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-20030229116-A1 | ENAMINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229116-A1 | ENAMINE DERIVATIVES | ITGB2, CCR1, CCR10 | FFAR1 172/4885DRD1 816/4885GRM4 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.